Whilst EDM 1410 was tabled in the last parliamentary session and has therefore lapsed, I recognise the challenges faced by many patients with chronic conditions in accessing medicinal cannabis, and note the issues being raised around prescribing cannabis medicines by healthcare professionals. I would be happy to raise this with the relevant Minister to make them aware of the strength of feeling on these issues.

I understand that, particularly for parents whose children are suffering or in pain, there is continued frustration that it is not easily accessible. Although the scheduling of cannabis-based products changed in 2018, this has not translated into significant clinical use.  

Each case is judged individually, and I believe that the decision should remain solely with the clinician. However, many doctors remain cautious in prescribing these treatments, and guidelines published by the National Institute for Health and Care Excellence (NICE) demonstrate a need for more evidence to justify routine prescribing of unlicensed cannabis-based products. NICE also made recommendations for further research to inform future decisions on the routine prescribing and funding of unlicensed cannabis-based medicines on the NHS.

The National Institute for Health and Care Research (NIHR) has issued two calls for research proposals and a highlight notice on medicinal cannabis. Manufacturers are responsible for generating evidence to support the use of these products and to seek regulatory approval. The Government encourages manufacturers to do so and offers scientific and research advice from the Medicines and Healthcare products Regulatory Agency and the NIHR.

Without a doubt, the number of patients with NHS prescriptions for medicinal cannabis products is low. Often families have sought private treatment, which is clearly a serious financial burden.

While the Government cannot stipulate what companies charge for the products, and these companies may face export or import fees for controlled drugs, I am aware of Ministers’ work within these constraints to reduce costs. Many believe medicinal cannabis, where clinically appropriate, is critical for patients and families in need, and I am assured that the Government is considering every possibility to ensure greater access.

My colleague, Alberto Costa MP, assures me that the All-Party Parliamentary Group on Medical Cannabis under Prescription will continue to do all it can on behalf of all those who are affected to try to ensure that they get the prescriptions and drugs they need.